| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02046187 Details | 2021-06-16 Interventional | 1/2 | 14 | Temozolomide Glioblastoma Glioblastoma (G… | excessive protocol deviations due to strict nature of diet requirements - | |||
| NCT03694197 2018-002810-11 Details | 2021-06-15 Interventional | 4 | 1389 | Alirocumab Hypercholestero… Hyperlipoprotei… Heterozygous Fa… Non-familial Hy… | The primary objective (to evaluate the long-term safety of Praluent) was adequately evaluated
in other studies. - | |||
| NCT03232749 Details | 2021-06-14 Interventional | 4 | 25 | Methylprednisol… Methylprednisol… Osteoarthritis Osteoarthritis … | The physician in charge is leaving the University of Florida - | |||
| NCT01436175 2011-003019-47 Details | 2021-06-14 Interventional | 3 | 1570 | Antidepressive … Lisdexamfetamin… Depression Depressive Diso… Depressive Diso… Major Depressiv… | SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination
was not related to any new safety findings. The study was terminated on 11 Feb 2014. SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings. | |||
| NCT00450333 2006-002052-15 Details | 2021-06-14 Interventional | 3 | 407 | Epoetin Alfa Anemia Renal Insuffici… Kidney Failure | The termination of the study is not linked to a product recall or result of any safety signal.
Rather it was sponsor's commercial decision to withdraw the MA This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses. | |||
| NCT01343823 Details | 2021-06-11 Interventional | 2 | [1 Refs] | 79 | Ecallantide Angioedema ACE Inhibitor I… | Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was
substantially higher than described in medical literature. The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early. | ||
| NCT01117051 2009-015652-20 Details | 2021-06-11 Interventional | 3 | 174 | Prucalopride Constipation Opioid-Induced … Non-cancer Pain Opioid Induced … | The study was stopped by the sponsor based on a non-safety related business priority decision Due to the early termination of the study, results should be interpreted with caution. | |||
| NCT04341935 Details | 2021-06-10 Interventional | 4 | [2 Refs] | 0 | Linagliptin COVID-19 Coronavirus Inf… Diabetes Mellit… Coronavirus Inf… Type 2 Diabetes | Logistical challenges amid COVID-19 pandemic and lack of financial support - | ||
| NCT02940223 Details | 2021-06-10 Interventional | 2 | 2 | Eicosapentaenoi… Fatigue Neoplasms Advanced Malign… | PI is requesting termination (closure) of this study. - | |||
| NCT02349633 Details | 2021-06-10 Interventional | 1/2 | 65 | Avelumab Palbociclib Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | The study was ended for strategic reasons and changes in the external environment.
The safety profile and risk benefit ratio for PF-0674775 remained unchanged. - | |||
| NCT03717012 Details | 2021-06-09 Interventional | 4 | 19 | Nintedanib Fibrosis Idiopathic Pulm… Pulmonary Fibro… | The trial was terminated prematurely due to difficulties with recruitment because of the
COVID-19 pandemic. Trial was terminated prematurely due to difficulties with recruitment and a global BI recruitment hold implemented on 17 March 2020 because of the COVID-19 pandemic. The recruitment rate was slow and the target number of participants to be recruited was not reached. No inferential statistical analysis was performed. | |||
| NCT03923257 Details | 2021-06-08 Interventional | 1/2 | 0 | Lutetium Lu 177… Neuroendocrine … Paraganglioma Pheochromocytom… | competing clinical trial opening - | |||
| NCT01433991 Details | 2021-06-08 Interventional | 1/2 | 30 | Lenvatinib Glioblastoma Advanced Solid … | Study was terminated by the sponsor early at the end of Phase 1b due to a change in corporate
strategy. The study was terminated by the sponsor at the end of Phase 1b due to a change in corporate strategy, hence Phase 2 was not carried out. | |||
| NCT04033562 Details | 2021-06-07 Interventional | 4 | 2 | Bupivacaine Lidocaine Opioid-Related … Ambu ACTion Cesarean Sectio… Infusion Cathet… Lidopatch Medication Assi… Opioid Abuse Opioid Dependen… Opioid Use Opioid-use Diso… Pregnancy Relat… | limited enrollment and unable to enroll subjects to reach statistical significance - | |||
| NCT03979820 2018-003965-32 Details | 2021-06-04 Interventional | 1 | 53 | Phenelzine Tyramine Healthy | Study discontinued - testing of highest dose obsolete The sponsor decided to permanently discontinue the trial on 14 April 2020 due to lock down of the trial site enforced by the Covid-19 pandemic. Therefore some of the planned analysis were not performed due to lack of data. | |||
| NCT04451174 Details | 2021-06-03 Interventional | 3 | 60 | Prednisone COVID-19 Pneumonia | Corticosteroid use approval - | |||
| NCT03605212 2016-001445-61 Details | 2021-06-03 Interventional | 1/2 | 30 | Febuxostat Syndrome Tumor Lysis Syn… | The study was stopped as per EMA waiver granted on 20July2018. Data for all outcome measures were not collected due to the paucity of data in the minor patient population and in agreement with EMA with the exceptions of the secondary outcome Assessment of Treatment Emergent Signs and Symptoms (TESS). | |||
| NCT01274221 Details | 2021-06-03 Interventional | 3 | 0 | Lisdexamfetamin… Attention Defic… ADHD | Cancellation was not safety related but a shift in study priorities for Shire. - | |||
| NCT01234298 Details | 2021-06-03 Interventional | 3 | 0 | Lisdexamfetamin… Schizophrenia Negative Sympto… | Study was discontinued due to non-safety related business prioritization decisions - | |||
| NCT04493229 Details | 2021-06-02 Interventional | 2 | 0 | Oxytocin Osteoarthritis,… | study team decided not to proceed with project - |